Log in

Relevant bibliographies by topics / Pharmaceutical Manufacturers Association of Canada / Journal articles

To see the other types of publications on this topic, follow the link: Pharmaceutical Manufacturers Association of Canada.

Journal articles on the topic 'Pharmaceutical Manufacturers Association of Canada'

Author: Grafiati

Published: 4 June 2021

Last updated: 28 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pharmaceutical Manufacturers Association of Canada.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Lexchin, Joel. "Canadian Marketing Codes: How Well are They Controlling Pharmaceutical Promotion?" International Journal of Health Services 24, no. 1 (1994): 91–104. http://dx.doi.org/10.2190/ekep-d9je-31a4-kte5.

Full text

Abstract:

Pharmaceutical promotion in Canada is controlled by two codes: a voluntary one developed by the Pharmaceutical Advertising Advisory Board dealing mostly with printed promotional material, and one from the Pharmaceutical Manufacturers Association of Canada covering other forms of promotion. This article looks at enforcement of the provisions of these codes and at areas in which they are deficient. One of the major weaknesses in both codes is their lack of effective sanctions for companies that violate their provisions. Strong codes are necessary because many physicians rely heavily on promotion

APA, Harvard, Vancouver, ISO, and other styles

2

Dolovich, Myrna B., and Jolyon P. Mitchell. "Canadian Standards Association Standard CAN/CSA/Z264.1-02:2002: A New Voluntary Standard for Spacers and Holding Chambers Used with Pressurized Metered-Dose Inhalers." Canadian Respiratory Journal 11, no. 7 (2004): 489–95. http://dx.doi.org/10.1155/2004/497946.

Full text

Abstract:

A new Canadian standard (CAN/CSA/Z264.1-02:2002) has been published with the purpose of helping to ensure the safety, efficacy and functionality of spacers and/or holding chambers. They are prescribed for use by spontaneously breathing patients for the treatment of various respiratory diseases where medication is delivered to the lungs using pressurized-metered dose inhalers. This consensus standard was developed with the support of pharmaceutical companies and manufacturers of spacers and holding chambers, and with the help of clinicians, retail pharmacists and representatives of patient advo

APA, Harvard, Vancouver, ISO, and other styles

3

Parke, Dennis V., Costas Ioannides, and David F. V. Lewis. "The 1990 Pharmaceutical Manufacturers Association of Canada Keynote Lecture. The role of the cytochromes P450 in the detoxication and activation of drugs and other chemicals." Canadian Journal of Physiology and Pharmacology 69, no. 5 (1991): 537–49. http://dx.doi.org/10.1139/y91-081.

Full text

Abstract:

The roles of the cytochromes P450 are reviewed, with emphasis on their involvement in the detoxication of drugs and chemicals, the activation of carcinogens, and the toxicity of drugs. Cytochromes P450 have different characteristics. P450I mostly activates carcinogens and other chemicals by forming oxygenated reactive intermediates, which are also associated with the formation of neoantigens and immunotoxicity. P450IIE has a propensity to form oxygen radicals, which are cytotoxic and carcinogenic; other cytochromes generate oxygen radicals by futile cycling when activated by difficultly metabo

APA, Harvard, Vancouver, ISO, and other styles

4

Clarke, Philippa, and Angela Colantonio. "Wheelchair Use Among Community-Dwelling Older Adults: Prevalence and Risk Factors in a National Sample." Canadian Journal on Aging / La Revue canadienne du vieillissement 24, no. 2 (2005): 191–98. http://dx.doi.org/10.1353/cja.2005.0059.

Full text

Abstract:

ABSTRACTOlder adults are the largest group of wheelchair users yet there are no peer-reviewed studies on the national profile of older wheelchair users in Canada. We investigated the characteristics of wheelchair users in a national sample of community-dwelling older adults from the Canadian Study of Health and Aging (CSHA-2). Questions on the use of assistive technology were asked of 5395 Canadians (over 64), and 4.6 per cent reported using a wheelchair. Logistic regression was used to model the factors associated with wheelchair use. Controlling for age, gender, and cognitive impairment, old

APA, Harvard, Vancouver, ISO, and other styles

5

Gerber, Patricia E., and Larry D. Lynd. "Selective Serotonin-Reuptake Inhibitor–Induced Movement Disorders." Annals of Pharmacotherapy 32, no. 6 (1998): 692–98. http://dx.doi.org/10.1345/aph.17302.

Full text

Abstract:

OBJECTIVE: To compile and evaluate all available data suggesting an association between selective serotonin-reuptake inhibitor (SSRI) administration and the occurrence of movement disorders, and to characterize these reactions in terms of onset, duration, treatment and outcome, and potential predisposing factors. METHODOLOGY: Reports of movement disorders were identified by conducting a comprehensive literature search that included tertiary adverse drug reaction resources, MEDLINE, EmBASE, Biological Abstracts, Current Contents, Reactions, ClinAlert, and International Pharmaceutical Abstracts.

APA, Harvard, Vancouver, ISO, and other styles

6

Kashyntseva, Oksana. "Pharmaceutical nationalism as an instrument to ensure the access to medicines." Theory and Practice of Intellectual Property, no. 2 (July 6, 2021): 101–6. http://dx.doi.org/10.33731/22021.236692.

Full text

Abstract:

Keywords: pharmaceutical nationalism, access to drugs, compulsory licensing, governmentuse, exclusion from intellectual property rights The article concerns the emergence of the phenomena of«pharmaceutical nationalism» in the year of the COVID-19 pandemic. Pharmaceuticalnationalism is manifested in the qualitative and quantitative aspects. In the contextof a qualitative manifestation of pharmaceutical nationalism, we presume the politicalwill on establishing of a new state protectionist policy to local manufacturers ofmedicines, the establishing of preferences, exemptions of the patent m

APA, Harvard, Vancouver, ISO, and other styles

7

Gardner, David M., and Larry D. Lynd. "Sumatriptan Contraindications and the Serotonin Syndrome." Annals of Pharmacotherapy 32, no. 1 (1998): 33–38. http://dx.doi.org/10.1345/aph.17204.

Full text

Abstract:

OBJECTIVE To determine the risk for serotonin syndrome associated with the concomitant use of sumatriptan and the currently contraindicated therapies, that is, the monoamine oxidase inhibitors (MAOIs), serotonin selective-reuptake inhibitors (SSRIs), and lithium. METHODOLOGY: A comprehensive search for reports of serotonin syndrome associated with sumatriptan use was conducted by using tertiary drug interaction literature, MEDLINE, EmBASE, Biological Abstracts, Current Contents, Reactions, ClinAlert, and the International Pharmaceutical Abstracts. In addition, related reports from the propriet

APA, Harvard, Vancouver, ISO, and other styles

8

Thanh, Nguyen Xuan, Anderson W. Chuck, Arto Ohinmaa, and Philip Jacobs. "BENEFITS OF PHARMACEUTICAL INNOVATION: THE CASE OF SIMVASTATIN IN CANADA." International Journal of Technology Assessment in Health Care 28, no. 4 (2012): 390–97. http://dx.doi.org/10.1017/s0266462312000499.

Full text

Abstract:

Background: The benefits of pharmaceutical innovations are widely diffused; they accrue to the healthcare providers, patients, employers, and manufacturers. We estimate the societal monetary benefits of simvastatin in Canada and its distribution among different beneficiaries overtime.Methods: Monetary benefits to developing and generic manufacturers were estimated by calculating public and private revenues minus the development costs of simvastatin and the contribution toward further research and development. We used a dynamic Markov model to estimate monetary benefits to healthcare and employ

APA, Harvard, Vancouver, ISO, and other styles

9

Weaver, Lawrence C. "A View from the Pharmaceutical Manufacturers Association." American Journal of Pharmaceutical Education 49, no. 4 (1985): 381–82. http://dx.doi.org/10.1016/s0002-9459(24)09956-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kobayashi, Satoshi. "DRUG INTERACTION WORKING GROUP : JAPAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION." Drug Metabolism and Pharmacokinetics 14, supplement (1999): 150–51. http://dx.doi.org/10.2133/dmpk.14.supplement_150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

KOBAYASHI, Satoshi. "Drug Interaction Working Group. Japan Pharmaceutical Manufacturers Association." Drug Metabolism and Pharmacokinetics 15, no. 3 (2000): 260–64. http://dx.doi.org/10.2133/dmpk.15.260.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

TAKAHASHI, Haruo. "From the Position of Japan Pharmaceutical Manufacturers Association (JPMA)." Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku 14, no. 1 (2009): 37–45. http://dx.doi.org/10.3820/jjpe.14.37.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

GABRIEL, JOSEPH M. "Pharmaceutical patenting and the transformation of American medical ethics." British Journal for the History of Science 49, no. 4 (2016): 577–600. http://dx.doi.org/10.1017/s0007087416001138.

Full text

Abstract:

AbstractThe attitudes of physicians and drug manufacturers in the US toward patenting pharmaceuticals changed dramatically from the mid-nineteenth century to the mid-twentieth. Formerly, physicians and reputable manufacturers argued that pharmaceutical patents prioritized profit over the advancement of medical science. Reputable manufactures refused to patent their goods and most physicians shunned patented products. However, moving into the early twentieth century, physicians and drug manufacturers grew increasingly comfortable with the idea of pharmaceutical patents. In 1912, for example, th

APA, Harvard, Vancouver, ISO, and other styles

14

Siegel, Andre, and James Hull. "Made in Canada! The Canadian Manufacturers’ Association’s Promotion of Canadian-Made Goods, 1911-1921." Journal of the Canadian Historical Association 25, no. 1 (2015): 1–31. http://dx.doi.org/10.7202/1032797ar.

Full text

Abstract:

Beginning just before WW1 and continuing into the postwar period, the Canadian Manufacturers’ Association mounted a campaign to sell Canadian consumers on the virtues of buying “Made in Canada” goods. Not simply an appeal to patriotism, this campaign had to convince Canadian consumers of the satisfactory quality of such goods — which manufacturers had to deliver the substance of — in an increasingly sophisticated retail and marketing environment. Such an encouragement of the demand side of the producer/consumer equation is an important example of the proactive stance taken by Canadian manufact

APA, Harvard, Vancouver, ISO, and other styles

15

Murayama, Anju, Kenichi Higuchi, and Yuki Senoo. "Financial Relationships Between Pharmaceutical Companies and Internal Medicine Societies." JAMA Network Open 7, no. 4 (2024): e244777. http://dx.doi.org/10.1001/jamanetworkopen.2024.4777.

Full text

Abstract:

This cross-sectional study uses payment data publicly disclosed by pharmaceutical companies affiliated with the Japan Pharmaceutical Manufacturers Association to describe their financial relationships with the subspecialty societies of the Japanese Society of Internal Medicine.

APA, Harvard, Vancouver, ISO, and other styles

16

DeLong, Deborah L., Robert A. Kozak, and David H. Cohen. "Overview of the Canadian value-added wood products sector and the competitive factors that contribute to its success." Canadian Journal of Forest Research 37, no. 11 (2007): 2211–26. http://dx.doi.org/10.1139/x07-027.

Full text

Abstract:

In recent years, there has been considerable interest in the secondary wood manufacturing sector across Canada. Strengthening and facilitating the secondary wood manufacturing or the value-added sector is seen as the next step to creating a more sustainable economy across Canada. This research considered a large sample of secondary wood manufacturers across Canada and has provided standardized information for the entire sector. To evaluate the competitive position of the Canadian secondary wood manufacturers, two steps were undertaken. First, factors that have determined success in other secto

APA, Harvard, Vancouver, ISO, and other styles

17

Christian, Mildred S. "Overview of the Fourth International Conference on Harmonization." International Journal of Toxicology 16, no. 6 (1997): 659–68. http://dx.doi.org/10.1080/109158197226955.

Full text

Abstract:

This overview of the Fourth International Conference on Harmonization (ICH 4), held in Brussels, Belgium, 16-18 July 1997, summarizes results and provides information regarding the nonclinical workshop and issued nonclinical testing guidelines [Draft Final (Step 4) Guidelines recommended for adoption to the regulatory bodies of the EU, Japan, and the USA]. ICH 4 completed the initial harmonization targets for the three ICH Regions [European Commission-European Union (EU) and European Federation of Pharmaceutical Industries' Association (EFPIA); Ministry of Health and Welfare (MHW) Japan and Ja

APA, Harvard, Vancouver, ISO, and other styles

18

Duarte-García, Alí, Cynthia S. Crowson, Rozalina G. McCoy, et al. "Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology." Mayo Clinic Proceedings 97, no. 2 (2022): 250–60. http://dx.doi.org/10.1016/j.mayocp.2021.08.026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Abhishek, Pawar* Abhishek Shrivastava Dr. Jitendra Banweer. "Impact Of Data Integrit on Pharmaceutical Industry ALCOA, ALCOA+, ALCOA++." International Journal of Pharmaceutical Sciences 3, no. 5 (2025): 824–29. https://doi.org/10.5281/zenodo.15344828.

Full text

Abstract:

As well as being crucial for compliance reasons, ALCOA+ principles are becoming increasingly important to GMP (Good Manufacturing Practices). Their relevance is also growing as manufacturers in the life sciences sector continue to implement Industry solutions and processes. changed, duplicated, or moved. In terms of data integrity, data refers to all original records, including source data and metadata, whether they are kept on paper or electronically. ALCOA was suggested by various regulatory organisations, including the USFDA, Health Canada, and EMEA, to ensure the integrity of the data Attr

APA, Harvard, Vancouver, ISO, and other styles

20

Segal, Richard, and Lorelei L. Grines. "Prescribing Authority for Pharmacists as Viewed by Organized Pharmacy, Organized Medicine, and the Pharmaceutical Industry." Drug Intelligence & Clinical Pharmacy 22, no. 3 (1988): 241–46. http://dx.doi.org/10.1177/106002808802200316.

Full text

Abstract:

This study identifies attitudes of organized pharmacy, organized medicine, and the pharmaceutical industry about prescribing authority for pharmacists. A questionnaire designed to assess the impact of a legislative bill permitting a pharmacist in an organized health care setting to initiate or modify drug therapy was mailed to state pharmacy associations, state hospital pharmacy associations, state pharmacy boards, state medical associations, Pharmaceutical Manufacturers Association (PMA)-member manufacturers, and non-PMA-member generic manufacturers. Responses from 194 of the 307 invited orga

APA, Harvard, Vancouver, ISO, and other styles

21

Rodwin, Marc A., and Sara Gerke. "German Pharmaceutical Pricing: Lessons for the United States." International Journal of Health Services 52, no. 1 (2021): 146–58. http://dx.doi.org/10.1177/00207314211040948.

Full text

Abstract:

To control pharmaceutical spending and improve access, the United States could adopt strategies similar to those introduced in Germany by the 2011 German Pharmaceutical Market Reorganization Act. In Germany, manufacturers sell new drugs immediately upon receiving marketing approval. During the first year, the German Federal Joint Committee assesses new drugs to determine their added medical benefit. It assigns them a score indicating their added benefit. New drugs comparable to drugs in a reference price group are assigned to that group and receive the same reimbursement, unless they are thera

APA, Harvard, Vancouver, ISO, and other styles

22

Matsuzawa, Toshiaki. "Present Status of Animal Clinical Pathology Examinations in the Japanese Pharmaceutical Manufacturers Association." Toxicologic Pathology 20, no. 3-2 (1992): 528–33. http://dx.doi.org/10.1177/0192623392020003214.

Full text

Abstract:

This paper will review the current status of animal clinical pathology in Japan using data obtained during a survey conducted by the Japanese Pharmaceutical Manufacturers Association (JPMA). I am presenting this information as a representative of the Non-Clinical Evaluation Committee of the JPMA. Two co-workers, Dr. Nomura of Daiichi Pharmaceutical Co., Ltd., and Dr. Unno of Kanebo Co., Ltd., are also involved in this effort. Investigating and discussing the various problems concerning animal clinical pathology is timely and truly heartening, and we expect this information exchange in the anim

APA, Harvard, Vancouver, ISO, and other styles

23

Shegokar, Yash, Sakshi Dhawad, Vinita Kale, Suankit Harane, and Milind Umekar. "Post-approval changes in Labelling regulations in the United States, European Union and Canada." International Journal of Drug Regulatory Affairs 12, no. 3 (2024): 5–12. http://dx.doi.org/10.22270/ijdra.v12i3.680.

Full text

Abstract:

The review “Post-approval changes in Labelling Regulations in the United States, Europe and Canada” goes into the details and consequences of post-approval changes in labeling regulations for pharmaceutical products. It covers the concept of post-approval changes and outlines the key areas of changes, such as various elements of product lifecycle management, market access, innovation, risk control, and legal compliance for manufacturers in the United States, Europe, and Canada. Apart from that, the abstract discusses the similarities and differences in labeling regulations across the regions i

APA, Harvard, Vancouver, ISO, and other styles

24

Veronin, Michael A., Eunah Lee, and E. Neil Lewis. "“Insight” into Drug Quality: Comparison of Simvastatin Tablets from the US and Canada Obtained via the Internet." Annals of Pharmacotherapy 41, no. 7-8 (2007): 1111–15. http://dx.doi.org/10.1345/aph.1h680.

Full text

Abstract:

Background: Recently, there has been much debate in the US concerning drug importation from Canadian Internet pharmacies. The Food and Drug Administration and US drug manufacturers assert that drugs obtained from international markets via the Internet present a health risk to consumers from substandard products. The public's perception is that drugs from Canada are as safe as those from the US. Objective: To determine whether simvastatin tablets obtained via the Internet from Canadian generic manufacturers are comparable in blend uniformity, a major attribute of tablet quality, with the US inn

APA, Harvard, Vancouver, ISO, and other styles

25

Chappell, Neena, Alan Cassels, Linda Outcalt, and Carren Dujela. "Conflict of interest in pharmaceutical policy research: an example from Canada." International Journal of Health Governance 21, no. 2 (2016): 66–75. http://dx.doi.org/10.1108/ijhg-03-2016-0016.

Full text

Abstract:

Purpose – There is much evidence of bias in research on the effectiveness and efficacy of drugs as a result of the influence of the pharmaceutical industry. The purpose of this paper is to present the views of those involved in a major evidence-based policy initiative from Canada and examine the adequacy of existing academic conflict of interest (COI) rules. Design/methodology/approach – Data came from the Alzheimer’s Drug Therapy Initiative in British Columbia, a coverage with evidence development (CED) initiative, where a form of action research collected insights from the authors’ experienc

APA, Harvard, Vancouver, ISO, and other styles

26

Diener, Robert M. "Harmonization of Drug Safety Guidelines: A Perspective from the Pharmaceuticals Industry." Journal of the American College of Toxicology 11, no. 3 (1992): 293–97. http://dx.doi.org/10.3109/10915819209141864.

Full text

Abstract:

The Pharmaceutical Manufacturers Association (PMA) and the International Federation of Pharmaceutical Manufacturers Association (IFPMA) have taken a leading role in the current harmonization efforts, which also include issues on quality assurance and clinical efficacy, although these subjects will not be addressed here. Important preclinical testing issues were identified by industry and regulatory expert working groups in Europe, Japan, and the United States. The most critical issues were then selected, and regulatory agencies in each country were encouraged to address the possible resolution

APA, Harvard, Vancouver, ISO, and other styles

27

Hollis, Aidan, and Peter Ibbott. "How Parallel Trade Affects Drug Policies and Prices in Canada and the United States." American Journal of Law & Medicine 32, no. 2-3 (2006): 193–217. http://dx.doi.org/10.1177/009885880603200204.

Full text

Abstract:

U.S. consumers and Canadian pharmacies have rushed to take advantage of the opportunity presented by price differences in patented pharmaceuticals. This rapidly growing parallel trade has brought the Canadian and U.S. systems for determining pharmaceutical pricing under increased scrutiny, and the pressure for change seems to be building. This paper examines why parallel trade in pharmaceuticals has grown and considers some of the policy options confronting both countries.To do this we begin by identifying similarities and differences in the Canadian and U.S. regulatory frameworks governing tr

APA, Harvard, Vancouver, ISO, and other styles

28

Roughead, E. E. "The Australian Pharmaceutical Manufacturers Association Code of Conduct: guiding the promotion of prescription medicines." Australian Prescriber 22, no. 4 (1999): 78–80. http://dx.doi.org/10.18773/austprescr.1999.067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Yoshikawa, Tsuyoshi, Yasushi Horai, Yoshiji Asaoka, et al. "Current status of pathological image analysis technology in pharmaceutical companies: a questionnaire survey of the Japan Pharmaceutical Manufacturers Association." Journal of Toxicologic Pathology 33, no. 2 (2020): 131–39. http://dx.doi.org/10.1293/tox.2019-0056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Singhania, Smita Suneel, and Krishan Kumar Tripathi. "India: Similar biologics guidelines and implementation." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 9, no. 4 (2012): 181–86. http://dx.doi.org/10.1177/1741134312466560.

Full text

Abstract:

Indian regulatory authorities for biologics, jointly at Department of Biotechnology and Central Drug Standard Control organization in association with the task force comprising Indian biologics manufacturers laid down the regulatory pathway for manufacturing and marketing authorization of similar biologics, claiming to be similar to an already authorized reference biologic. This guidance has come in force from 15 September 2012 in India. This guidance document is a simple abridged process for evaluation of ‘Similar Biologics’ that are approved and marketed either in India, Europe or USA or any

APA, Harvard, Vancouver, ISO, and other styles

31

Boumil, Marcia M., Emily S. Cutrell, Kathleen E. Lowney, and Harris A. Berman. "Pharmaceutical Speakers' Bureaus, Academic Freedom, and the Management of Promotional Speaking at Academic Medical Centers." Journal of Law, Medicine & Ethics 40, no. 2 (2012): 311–25. http://dx.doi.org/10.1111/j.1748-720x.2012.00666.x.

Full text

Abstract:

Pharmaceutical companies routinely engage physicians, particularly those with prestigious academic credentials, to deliver educational talks to groups of physicians in the community to help market the company's brand-name drugs. These speakers receive substantial compensation to lecture at events sponsored by pharmaceutical companies, a practice that has garnered attention, controversy, and scrutiny in recent years from legislators, professional associations, researchers, and ethicists on the issue of whether it is appropriate for academic physicians to serve in a promotional role. These relat

APA, Harvard, Vancouver, ISO, and other styles

32

Singh, Ranjita, Philip Walsh, and Joshua Goodfield. "Innovation cognizance and acceptance: The case of electric vehicles adoption in Ontario, Canada." Journal of Innovation Management 9, no. 1 (2021): 51–69. http://dx.doi.org/10.24840/2183-0606_009.001_0005.

Full text

Abstract:

This study examines the results of a survey of 1,000 Canadian internal combustion engine (ICE) vehicle owners to assess factors that would encourage them to purchase an electric vehicle (EV). Further to the work of Peters and Dutschke (2014) and (Matthews et al. (2017) we combine the various drivers of EV adoption, independently identified in the literature, into one model in order to investigate their influence on the intent to purchase an EV. Through correlations and a series of probit regression modelling, we provide evidence to support additional policies that could establish greater relat

APA, Harvard, Vancouver, ISO, and other styles

33

L., J. F. "PMA SURVEY IDENTIFIES 114 DRUGS, VACCINES IN DEVELOPMENT FOR CHILDREN." Pediatrics 88, no. 5 (1991): 986. http://dx.doi.org/10.1542/peds.88.5.986.

Full text

Abstract:

WASHINGTON, D. C.—The first-ever survey to identify pediatric medicines in development has found that 114 drugs and vaccines are in testing for use in children. The survey, conducted by Pharmaceutical Manufacturers Association, revealed that these medicines are involved in 127 research projects, because some are being tested for more than one use. "The results of this survey are remarkable considering the difficulties of testing drugs in children," said PMA President Gerald J. Mossinghoff. "Although researchers are faced with problems of recruitment, safety and costs for pediatric clinical tri

APA, Harvard, Vancouver, ISO, and other styles

34

Anantha Narayana, D. B. "THE SKILLING INDIAN SCIENTISTS FOR LAST OVER FIVE DECADES." INDIAN DRUGS 54, no. 11 (2017): 5–6. http://dx.doi.org/10.53879/id.54.11.p0005.

Full text

Abstract:

Indian Drug Manufacturers’ Association (IDMA) was formed in 1961, exactly 56 years ago. It started publishing “Indian Drugs” a publication devoted to various aspects, amongst which were “giving space for Indian Pharmaceutical Scientists and others to find a place to publish the results of their research”. Indian Drugs - monthly scientific and technical journal has completed its Golden Jubilee last year and is now in its 53rd year. Indian Drugs is also an online version with dedicated website www.indiandrugsonline.org apart from bringing out the Print version still.

APA, Harvard, Vancouver, ISO, and other styles

35

Basova, E. M., Yu N. Litvinenko, and N. А. Polotnyanko. "PHARMACEUTICAL FORMULATION MANUFACTURER DISCRIMINATION BY INFRARED SPECTROSCOPY AND PRINCIPAL COMPONENT ANALYSIS." Bulletin of Dubna International University for Nature, Society, and Man. Series: Natural and engineering sciences, no. 2 (43) (December 24, 2019): 7–15. http://dx.doi.org/10.37005/1818-0744-2019-2-7-15.

Full text

Abstract:

In the present work Fournier transform infrared (IR) spectroscopy in association with chemometric technique was employed to identify kind of tablet formulations containing paracetamol and/or caffeine as active pharmaceutical ingredients. 13 samples of 5 commercially available brand tablets of different manufacturers and batches were bayed in local pharmacies. IR spectra of samples were recorded in the range 600—4000 cm-1 and subjected to and principal component analysis (PCA) which allowed to clearly identify 5 clusters in the scores plot using the third and the second principal components, co

APA, Harvard, Vancouver, ISO, and other styles

36

Panic, Gea, Xuan Yao, Paul Gregory, and Zubin Austin. "How do community pharmacies in Ontario manage drug shortage problems? Results of an exploratory qualitative study." Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 153, no. 6 (2020): 371–77. http://dx.doi.org/10.1177/1715163520958023.

Full text

Abstract:

Background: Pharmacists report spending a considerable amount of time dealing with drug shortages. There is no research in Canada identifying and describing the strategies and resources that pharmacists use to minimize disruption and continuity of care for patients. Methods: An exploratory qualitative methodology was used. Community pharmacists and technicians in Ontario were interviewed using a semi-structured protocol. Verbatim transcripts were generated and coded by at least 2 independent reviewers using content analysis methods to identify management strategies. Results and Discussion: A t

APA, Harvard, Vancouver, ISO, and other styles

37

Barnato, Sara E., Simone N. Boyle, Adam Kuykendal, et al. "Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines." Blood 112, no. 11 (2008): 672. http://dx.doi.org/10.1182/blood.v112.11.672.672.

Full text

Abstract:

Abstract Studies have found that when investigators have financial relationships with pharmaceutical manufacturers, they are less likely to criticize the safety, efficacy, or cost-effectiveness of agents supplied by the manufacturers. No study has evaluated the possibility of an association between basic science findings and pharmaceutical funding. This is important for erythropoietic stimulating agents (ESAs), where statements from the Centers for Medicaid and Medicaid Services, FDA, the National Comprehensive Cancer Network, the manufacturers, and the European Medicines Agency highlight tumo

APA, Harvard, Vancouver, ISO, and other styles

38

Rehan, Harmeet Singh, M. A. Nagarani, and M. Rehan. "EVALUATION OF DRUG ADVERTISEMENTS IN A MEDICAL JOURNALThough ideally the scientific information provided by pharmaceutical companies in drug advertisements should be for promotion of rational use of drugs, this objective is rarely achieved, as often the d." Journal of Nepal Medical Association 40, no. 140 (2003): 196–200. http://dx.doi.org/10.31729/jnma.671.

Full text

Abstract:

Though ideally the scientific information provided by pharmaceutical companies indrug advertisements should be for promotion of rational use of drugs, this objective israrely achieved, as often the data is incomplete and biased. Analytical studies withthe help of standard indicators on this aspect of drug advertisements are very fewfrom developing countries. We analyzed all medical drug advertisements in elevenconsecutive issues of Journal of Nepal Medical Association published between 1993and 1996 with a special emphasis on their conformity with WHO guidelines andInternational Federation of P

APA, Harvard, Vancouver, ISO, and other styles

39

Dangi, Ravi Raj, Amol Adkonkar, Pooja Arora, and Anand Sharma. "Impact of Information, Technology Infrastructure, Inventory Management and Demand on the Overall Performance of the Pharmaceutical Supply Chain." Paradigm: A Management Research Journal 27, no. 2 (2023): 211–28. http://dx.doi.org/10.1177/09718907231208761.

Full text

Abstract:

This study was conducted primarily to investigate the impact of information, technology, inventory management and demand on the performance of the pharmaceutical supply chain (PSC). In order to realize the objectives, a structured closed-ended questionnaire was prepared, and responses were collected from retail outlets considering the respondent’s location, size of the store, type of store and association of the store with manufacturers/companies. In total, 103 complete responses were used for the study. It was found that information, technology infrastructure, inventory management and demand

APA, Harvard, Vancouver, ISO, and other styles

40

KOREN, GIDEON. "Drug Errors." Pediatrics 80, no. 2 (1987): 308. http://dx.doi.org/10.1542/peds.80.2.308b.

Full text

Abstract:

In Reply.— In Canada, pediatric Lanoxin is available, as stated in our article, in a concentration of 0.05 mg/mL (Compendium of Pharmaceuticals and Specialties, ed 21. Ottawa, Canadian Pharmaceutical Association, 1986). This is another source of errors; physicians today moving from country to country should always check the stock solutions of drugs available and not assume that they are the same as at home.

APA, Harvard, Vancouver, ISO, and other styles

41

Valachis, Antonis, Nikolaos P. Polyzos, Andreas Nearchou, Pehr Lind, and Davide Mauri. "Financial Relationships in Economic Analyses of Targeted Therapies in Oncology." Journal of Clinical Oncology 30, no. 12 (2012): 1316–20. http://dx.doi.org/10.1200/jco.2011.38.6078.

Full text

Abstract:

Purpose A potential financial relationship between investigators and pharmaceutical manufacturers has been associated with an increased likelihood of reporting favorable conclusions about a sponsor's proprietary agent in pharmacoeconomic studies. The purpose of this study is to investigate whether there is an association between financial relationships and outcome in economic analyses of new targeted therapies in oncology. Materials and Methods We searched PubMed (last update June 2011) for economic analyses of targeted therapies (including monoclonal antibodies, tyrosine-kinase inhibitors, an

APA, Harvard, Vancouver, ISO, and other styles

42

Bombelles, Thomas. "Commentary: A Merck Perspective on the Doha Round." Global Economy Journal 5, no. 4 (2005): 1850073. http://dx.doi.org/10.2202/1524-5861.1160.

Full text

Abstract:

Commentary on the Doha Development Round from a representative of Merck. Thomas Bombelles is Director, International Government Relations, for Merck & Co., Inc. His responsibilities include definition and advocacy on important international business and policy issues for the company focusing on government agencies and other institutions in Washington, DC. Prior to joining Merck, Bombelles was the Assistant Vice President International at the Pharmaceutical Research and Manufacturers of America (PhRMA), the professional association representing the American research-based pharmaceutical ind

APA, Harvard, Vancouver, ISO, and other styles

43

Ball, Graeme, Mitchell A. H. Levine, Lehana Thabane, and Jean-Eric Tarride. "Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia." Current Oncology 29, no. 10 (2022): 7624–36. http://dx.doi.org/10.3390/curroncol29100602.

Full text

Abstract:

Publicly funded healthcare systems, including those in Canada, the United Kingdom (UK), and Australia, often use health technology assessment (HTA) to inform drug reimbursement decision-making, based on dossiers submitted by manufacturers, and HTA agencies issue publicly available reports to support funding recommendations. However, the level of information reported by HTA agencies in these reports may vary. To provide insights on this issue, we describe and assess the reporting of economic methods in recent oncology HTA recommendations from the Canadian Agency for Drugs and Technologies in He

APA, Harvard, Vancouver, ISO, and other styles

44

Pankaj, Kumar* Bharti Mangla2 Satbir Singh Arapna Rana. "GENERIC DRUG IN GLOBAL MARKET AND REGULATORY ENVIRONMENT." Indo American Journal of Pharmaceutical Sciences 04, no. 12 (2017): 4705–19. https://doi.org/10.5281/zenodo.1079864.

Full text

Abstract:

Different regulatory authorities regulate the drug development in various countries of the world. Various Regulatory authority for generic drug application Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical and Medical Devices Agency (PMDA), Health Product and Food Branch (HPFB) Central Drug Standard of Organization (CDSO). Generic manufacturers may file an abbreviated New Drug Application (ANDA) that incorporates the safety/effectiveness data submitted by original innovator drug manufacturer and adds only bioequivalence studies. Therefore it is very difficult

APA, Harvard, Vancouver, ISO, and other styles

45

Horodetska, I. Ya, and O. B. Blavatska. "Research of the current state of the vitaminary preparations market in Ukraine." Farmatsevtychnyi zhurnal, no. 5 (October 29, 2019): 3–11. http://dx.doi.org/10.32352/0367-3057.5.19.01.

Full text

Abstract:

Recently, the popularization of obligatory preventive use of multivitamin preparations has been observed, and, as a result of this, they have become an integral part of the modern lifestyle. This is precisely what determines the relevance and necessity of researching the market of vitamin and mineral complexes in Ukraine. A feature of the current state of the vitamin market is their positioning in the form of both drugs and dietary supplements (DS). In view of this, research of the assortment dynamics of product range, the features of the competitive environment for this group of drugs a

APA, Harvard, Vancouver, ISO, and other styles

46

Goto, Akihiko, Sadahiro Abe, Shoko Koshiba, Koji Yamaguchi, Nobuo Sato, and Yoshikazu Kurahashi. "Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA)." Drug Metabolism and Pharmacokinetics 34, no. 2 (2019): 148–54. http://dx.doi.org/10.1016/j.dmpk.2019.01.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Wang, George, and Richard Macaulay. "VP07 Cost-Effectiveness Of HTA Fees." International Journal of Technology Assessment in Health Care 35, S1 (2019): 77. http://dx.doi.org/10.1017/s0266462319002873.

Full text

Abstract:

IntroductionHealth technology assessment (HTA) bodies evaluate the clinical and/or economic impact of new therapies to inform public reimbursement decision-making. This research evaluates the value for money of current or proposed fees for HTA in countries with mandatory cost-effectiveness HTA bodies relative to their respective public drug expenditure.MethodsHTA appraisal fees were identified from publicly-available websites: National Institute for Health and Care Excellence (NICE), Canadian Agency for Drugs and Technologies in Health (CADTH), Institut National d'Excellence en Santé et Servic

APA, Harvard, Vancouver, ISO, and other styles

48

ALmasarweh, Mohammad Salameh Yousef. "The Impact of Human Capital on Competitive Performance: An Empirical Study on Jordanian Pharmaceutical Companies." European Scientific Journal, ESJ 12, no. 4 (2016): 68. http://dx.doi.org/10.19044/esj.2016.v12n4p68.

Full text

Abstract:

The study is aimed at knowing the impact of human capital on competitive performance in Jordanian pharmaceutical companies. The study sample consisted of Jordanian human medicines manufacturing companies listed in the Jordanian Association of Pharmaceutical Manufacturers’ records of manufacturing companies for 2015. This amounted to 15 companies. The sampling unit and the analysis included individuals working in these companies from managers to department heads at various administrative levels. To achieve its objectives, the study used descriptive analytical method. This method was applied to

APA, Harvard, Vancouver, ISO, and other styles

49

MAEDA, Shoutaro, Kanae TOGO, Musashi ISHIGURO, et al. "A Questionnaire Survey of Pharmaceutical Companies Affiliated with Japan Pharmaceutical Manufacturers Association on Current Use of Big Data/Real-World Data for Drug Development in Japan." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 50, no. 4 (2019): 167–75. http://dx.doi.org/10.3999/jscpt.50.167.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Newton, Skye, Hayley Hill, and Tracy Merlin. "OD09 How Are Population/Intervention/Comparator/Outcomes Criteria For Pharmaceutical Assessments Determined Around The World?" International Journal of Technology Assessment in Health Care 40, S1 (2024): S38. https://doi.org/10.1017/s0266462324001454.

Full text

Abstract:

IntroductionDefining the population, intervention, comparator, outcomes (PICO) criteria is an essential step prior to performing a health technology assessment (HTA), but variations exist in how this step is performed.MethodsA scoping review was performed to compare the processes and guidance provided for developing the PICO criteria for the assessment of new medicines across Australia, the UK, Canada, the US, European Union (as a single jurisdiction), Germany, France, the Netherlands, South Korea, and Taiwan. The websites of HTA agencies in these jurisdictions were searched for methodological

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!